StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd.

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)

Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –

BeOne Medicines Internal R&D Expense by Year

Internal R&D Expense ($M) ($M)

QuarterlyAnnual

BeOne Medicines Internal R&D Expense: $1,287M in FY2025, up 5.1% from a year earlier. That is the highest of the 10 years on record here.

Latest, FY2025
1,287
Period ended Dec 31, 2025
Change on a year earlier
+5.1%
1,225 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below

Where the FY2025 figure comes from

“|| Internal research and development expenses | 1,287,148 | 1,224,635 | 62,513 | 5.1 | %”

Source: Form 10-K (filed 2026-02-26) ↗

Reported in Form 10-Q / 10-K MD&A R&D Expense Summary Table.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedInternal R&D Expense ($M) ($M)Year on yearSource
FY2025Dec 31, 20251,287+5.1%Form 10-K (filed 2026-02-26) ↗
FY2024Dec 31, 20241,225+8.7%Form 10-K (filed 2025-02-27) ↗
FY2023Dec 31, 20231,127+12.3%Form 10-K (filed 2024-02-26) ↗
FY2022Dec 31, 20221,003+28.2%Form 10-K (filed 2023-02-27) ↗
FY2021Dec 31, 2021783+38.3%Form 10-K (filed 2022-02-28) ↗
FY2020Dec 31, 2020566+43.7%Form 10-K (filed 2021-02-25) ↗
FY2019Dec 31, 2019394+207.0%Form 10-K (filed 2021-02-25) ↗
FY2018Dec 31, 2018128+241.3%Form 10-K (filed 2019-02-28) ↗
FY2017Dec 31, 201737.60.0%Form 10-K (filed 2018-02-28) ↗
FY2016Dec 31, 201637.6–Form 10-K (filed 2018-02-28) ↗

Cite this data

StockData. (2026). BeOne Medicines Internal R&D Expense ($M), annual FY2016–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-internal

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.